Aptorum is Hong Kong based, US listed company (Mcap $100m) focused on generating late stage clinical candidates by developing already approved drugs for new orphan indications, as well as infectious diseases.
• SACT-1 for Neuroblastoma – ph2/3 trial planned for 2H’20
• SACT-COV19 – COVID-19 treatment - preclinical
17/F, Guangdong Investment Tower
148 Connaught Road
Hong Kong, Hong Kong Island 999077
Top 10 Holders of Aptorum Group Limited Class A
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by